{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:59:39Z","timestamp":1792054779939,"version":"4.4.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,20]]},"DOI":"10.1093\/jnci\/djj358","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T21:16:47Z","timestamp":1158700607000},"page":"1292-1301","source":"Crossref","is-referenced-by-count":127,"title":["Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma"],"prefix":"10.1093","volume":"98","author":[{"given":"Susana","family":"Inog\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Rodr\u00ecguez-Calvillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Zabalegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ascensi\u00f2n","family":"L\u00f2pez-D\u00ecaz de Cerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arancha","family":"Rodr\u00edguez-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Garc\u00eda-Mu\u00f1\u00f3z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"P\u00e8rez-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Bendandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,9,20]]},"reference":[{"key":"key\n\t\t\t\t20171012211912_BIB1","doi-asserted-by":"crossref","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol2005 ; 23 : 8447 \u201352.","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"key\n\t\t\t\t20171012211912_BIB2","doi-asserted-by":"crossref","unstructured":"Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal AS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol1986 ; 4 : 1470 \u201380.","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"key\n\t\t\t\t20171012211912_BIB3","doi-asserted-by":"crossref","unstructured":"Rohatiner AZS, Lister TA. The clinical course of follicular lymphoma. Best Pract Res Clin Haematol2005 ; 18 : 1 \u201310.","DOI":"10.1016\/j.beha.2004.06.002"},{"key":"key\n\t\t\t\t20171012211912_BIB4","doi-asserted-by":"crossref","unstructured":"Johnson PWM, Rohatiner AZS, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol1995 ; 13 : 140 \u20137.","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"key\n\t\t\t\t20171012211912_BIB5","doi-asserted-by":"crossref","unstructured":"Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood1999 ; 94 : 3325 \u201333.","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"key\n\t\t\t\t20171012211912_BIB6","doi-asserted-by":"crossref","unstructured":"Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol2005 ; 23 : 6421 \u20138.","DOI":"10.1200\/JCO.2005.06.004"},{"key":"key\n\t\t\t\t20171012211912_BIB7","doi-asserted-by":"crossref","unstructured":"Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev Anticancer Ther2001 ; 1 : 65 \u201372.","DOI":"10.1586\/14737140.1.1.65"},{"key":"key\n\t\t\t\t20171012211912_BIB8","doi-asserted-by":"crossref","unstructured":"Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med1992 ; 327 : 1209 \u201315.","DOI":"10.1056\/NEJM199210223271705"},{"key":"key\n\t\t\t\t20171012211912_BIB9","doi-asserted-by":"crossref","unstructured":"Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med1999 ; 5 : 1171 \u20137.","DOI":"10.1038\/13928"},{"key":"key\n\t\t\t\t20171012211912_BIB10","doi-asserted-by":"crossref","unstructured":"Weng WK, Czerwinski DK, Timmerman JM, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol2004 ; 22 : 4717 \u201324.","DOI":"10.1200\/JCO.2004.06.003"},{"key":"key\n\t\t\t\t20171012211912_BIB11","doi-asserted-by":"crossref","unstructured":"Hsu FJ, Caspar CB, Czerwinski DK, Kwak LW, Liles TM, Syrengelas A, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long term results of a clinical trial. Blood1997 ; 89 : 3129 \u201335.","DOI":"10.1182\/blood.V89.9.3129"},{"key":"key\n\t\t\t\t20171012211912_BIB12","unstructured":"Barrios Y, Cabrera R, Y\u00e1\u00f1ez R, Briz M, Plaza A, Fores M, et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica2002 ; 87 : 400 \u20137."},{"key":"key\n\t\t\t\t20171012211912_BIB13","doi-asserted-by":"crossref","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med2004 ; 351 : 2159 \u201369.","DOI":"10.1056\/NEJMoa041869"},{"key":"key\n\t\t\t\t20171012211912_BIB14","doi-asserted-by":"crossref","unstructured":"Bendandi M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration? Rev Recent Clin Trials2006 ; 1 : 67 \u201374.","DOI":"10.2174\/157488706775246120"},{"key":"key\n\t\t\t\t20171012211912_BIB15","doi-asserted-by":"crossref","unstructured":"Carroll WL, Thielemans K, Dilley J, Levy R. Mouse \u00d7 human heterohybridomas as fusion partners with human B-cell tumors. J Immunol Methods1986 ; 89 : 61 \u201372.","DOI":"10.1016\/0022-1759(86)90032-3"},{"key":"key\n\t\t\t\t20171012211912_BIB16","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Calvillo M, Inog\u00e9s S, L\u00f3pez-D\u00edaz de Cerio A, Zabalegui N, Villanueva H, Bendandi M. Variations in \u201crescuability\u201d of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit Rev Oncol Hematol2004 ; 52 : 1 \u20137.","DOI":"10.1016\/j.critrevonc.2004.05.002"},{"key":"key\n\t\t\t\t20171012211912_BIB17","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol1999 ; 17 : 1244 \u201353.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"key\n\t\t\t\t20171012211912_BIB18","doi-asserted-by":"crossref","unstructured":"Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol2005 ; 23 : 4652 \u201361.","DOI":"10.1200\/JCO.2005.01.891"},{"key":"key\n\t\t\t\t20171012211912_BIB19","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Baskar S, Gause BL, Kobrin CB, Watson TM, Frye AR, et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res2004 ; 10 : 8309 \u201317.","DOI":"10.1158\/1078-0432.CCR-04-1071"},{"key":"key\n\t\t\t\t20171012211912_BIB20","doi-asserted-by":"crossref","unstructured":"Rodriguez-Caballero A, Garc\u00eda-Manero AC, Bueno C, Almeida J, Varro R, Chen R, et al. A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Lab Invest2004 ; 84 : 1387 \u201398.","DOI":"10.1038\/labinvest.3700162"},{"key":"key\n\t\t\t\t20171012211912_BIB21","doi-asserted-by":"crossref","unstructured":"Bendandi M, Rodr\u00edguez-Calvillo M, Inog\u00e9s S, L\u00f3pez-D\u00edaz de Cerio A, P\u00e9rez Sim\u00f3n JA, Rodr\u00edguez Caballero A, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma2006 ; 47 : 29 \u201337.","DOI":"10.1080\/10428190500272473"},{"key":"key\n\t\t\t\t20171012211912_BIB22","doi-asserted-by":"crossref","unstructured":"Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype. Blood1997 ; 90 : 1109 \u201314.","DOI":"10.1016\/S0165-2478(97)85823-3"},{"key":"key\n\t\t\t\t20171012211912_BIB23","doi-asserted-by":"crossref","unstructured":"Jiang XM, Arepally G, Poncz M, McKenzie SE. Rapid detection of the Fc gamma RIIA-H\/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods1996 ; 199 : 55 \u20139.","DOI":"10.1016\/S0022-1759(96)00164-0"},{"key":"key\n\t\t\t\t20171012211912_BIB24","doi-asserted-by":"crossref","unstructured":"Van Dongen JJM, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia2003 ; 17 : 2257 \u2013317.","DOI":"10.1038\/sj.leu.2403202"},{"key":"key\n\t\t\t\t20171012211912_BIB25","doi-asserted-by":"crossref","unstructured":"Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M, et al. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol2001 ; 29 : 183 \u201393.","DOI":"10.1016\/S0301-472X(00)00651-2"},{"key":"key\n\t\t\t\t20171012211912_BIB26","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez ML, Almeida J, Vidriales B, L\u00f3pez-B\u00e9rges MC, Garc\u00eda-Marcos MA, Moro MJ, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia2002 ; 16 : 1460 \u20139.","DOI":"10.1038\/sj.leu.2402584"},{"key":"key\n\t\t\t\t20171012211912_BIB27","doi-asserted-by":"crossref","unstructured":"Woolson RF, O'Gorman TW. A comparison of several tests for censored paired data. Stat Med1992 ; 11 : 193 \u2013208.","DOI":"10.1002\/sim.4780110206"},{"key":"key\n\t\t\t\t20171012211912_BIB28","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol2004 ; 22 : 2654 \u201361.","DOI":"10.1200\/JCO.2004.07.170"},{"key":"key\n\t\t\t\t20171012211912_BIB29","doi-asserted-by":"crossref","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood2004 ; 104 : 1258 \u201365.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"key\n\t\t\t\t20171012211912_BIB30","doi-asserted-by":"crossref","unstructured":"Montoto S, L\u00f3pez-Guillermo A, Alt\u00e9s A, Perea G, Ferrer A, Camos M, et al. Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol2004 ; 15 : 1484 \u20139.","DOI":"10.1093\/annonc\/mdh406"},{"key":"key\n\t\t\t\t20171012211912_BIB31","doi-asserted-by":"crossref","unstructured":"Kobrin CB, Bendandi M, Kwak LW. Novel secondary Ig VH gene rearrangement and in-frame Ig heavy chain complementarity-determining region III insertion\/deletion variants in de novo follicular lymphoma. J Immunol2001 ; 166 : 2235 \u201343.","DOI":"10.4049\/jimmunol.166.4.2235"},{"key":"key\n\t\t\t\t20171012211912_BIB32","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med2005 ; 11 : 986 \u201391.","DOI":"10.1038\/nm1290"},{"key":"key\n\t\t\t\t20171012211912_BIB33","doi-asserted-by":"crossref","unstructured":"Coscia M, Kwak LW. Therapeutic idiotype vaccines in B lymphoproliferative diseases. Expert Opin Biol Ther2004 ; 4 : 959 \u201363.","DOI":"10.1517\/14712598.4.6.959"},{"key":"key\n\t\t\t\t20171012211912_BIB34","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood2002 ; 99 : 856 \u201362.","DOI":"10.1182\/blood.V99.3.856"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/98\/18\/1292\/7687687\/djj358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T08:30:45Z","timestamp":1587198645000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jnci\/article\/98\/18\/1292\/2521764\/Clinical-Benefit-Associated-With-Idiotypic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,20]]},"references-count":34,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2006,9,20]]},"published-print":{"date-parts":[[2006,9,20]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djj358","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,9,20]]},"published":{"date-parts":[[2006,9,20]]}}}